Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 4:56 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 275 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Dextrose solution Clear all
Active, not recruiting Phase 3 Interventional

Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)

NCT04895358
View directory record Official record
Conditions
Breast Neoplasms
Interventions
pembrolizumab, paclitaxel, nab-paclitaxel, liposomal doxorubicin, capecitabine, normal saline, dextrose
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
342 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
41
States / cities
Birmingham, Alabama • Tucson, Arizona • Monterey, California + 33 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 19, 2026, 4:56 PM EDT
Completed Phase 4 Interventional Results available

Efficacy Assessment of Insulin Glargine Versus LiraglutidE After Oral Agents Failure

NCT01117350
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Insulin glargine, Liraglutide, Metformin
Drug
Lead sponsor
Sanofi
Industry
Eligibility
35 Years to 75 Years
Enrollment
978 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
45
States / cities
Birmingham, Alabama • Goodyear, Arizona • Phoenix, Arizona + 39 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2014 · Synced Oct 19, 2026, 4:56 PM EDT
Completed Phase 1 Interventional Results available

Ketones, Muscle Metabolism, and SGLT2 Inhibitors - Protocol 1

NCT03560323
View directory record Official record
Conditions
Heart Failure, Type 2 Diabetes Mellitus
Interventions
Beta-hydroxy-butyrate
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 80 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
2
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 29, 2025 · Synced Oct 19, 2026, 4:56 PM EDT
Completed Phase 1 Interventional

Rapid Administration of Insulin in Sepsis

NCT00823108
View directory record Official record
Conditions
Septic Shock
Interventions
GIK
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 25, 2022 · Synced Oct 19, 2026, 4:56 PM EDT
Not listed Not applicable Interventional

Evidence for Health Improvement in People With Diabetes Using One Touch & Partner Solutions

NCT05354297
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Cecelia Health plus OneTouch Verio Reflect® BGM and OneTouch Reveal® mobile app, Fitbit plus OneTouch Verio Reflect® BGM and OneTouch Reveal® mobile app, Noom plus OneTouch Verio Reflect® BGM and OneTouch Reveal® mobile app, Welldoc plus OneTouch Verio Reflect® BGM and Welldoc app
Device
Lead sponsor
LifeScan
Industry
Eligibility
18 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
San Mateo, California
Source: ClinicalTrials.gov public record
Updated Jul 20, 2022 · Synced Oct 19, 2026, 4:56 PM EDT
Terminated Phase 2 Interventional Results available

Safety and Efficacy of Abatacept Versus Placebo in Participants With Psoriatic Arthritis

NCT00534313
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Abatacept, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
191 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
19
States / cities
Huntsville, Alabama • Palm Desert, California • Palo Alto, California + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2012 · Synced Oct 19, 2026, 4:56 PM EDT
Recruiting Phase 1Phase 2 Interventional

Use of Phenylephrine for Assessment of Mitral Regurgitation Severity

NCT04500899
View directory record Official record
Conditions
Mitral Regurgitation
Interventions
Mydfrin
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 20, 2025 · Synced Oct 19, 2026, 4:56 PM EDT
Completed Early Phase 1 Interventional Results available

Adrenergic System in Islet Transplantation

NCT03079921
View directory record Official record
Conditions
Type1diabetes, Hypoglycemia, Hypoglycemia Unawareness, Islet Cell Transplantation
Interventions
Phentolamine, Propranolol, Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
21 Years to 65 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Oct 19, 2026, 4:56 PM EDT
Completed Not applicable Interventional Results available

Behavioral Approaches to Reducing Diabetes Distress and Improving Glycemic Control

NCT04016558
View directory record Official record
Conditions
Type 1 Diabetes, Diabetes Distress
Interventions
StreamLine, TunedIn, FixIt
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
19 Years and older
Enrollment
296 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 28, 2025 · Synced Oct 19, 2026, 4:56 PM EDT
Completed Not applicable Interventional

Urinary Tract Infections Rates Using 50% Dextrose Plus Washout Versus Normal Saline as Cystoscopy Fluid

NCT03719755
View directory record Official record
Conditions
Hysterectomy
Interventions
50% dextrose, Normal Saline
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
Female only
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 30, 2025 · Synced Oct 19, 2026, 4:56 PM EDT
Completed Phase 3 Interventional Results available

Phase 3 Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Versus Placebo in Addition to Paclitaxel and Carboplatin

NCT01285609
View directory record Official record
Conditions
Lung Cancer - Non Small Cell Squamous
Interventions
Ipilimumab, Placebo, Paclitaxel, Carboplatin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
1,289 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
33
States / cities
San Diego, California • West Haven, Connecticut • Boca Raton, Florida + 29 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2020 · Synced Oct 19, 2026, 4:56 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Racial Differences in the Natriuretic Peptide Response to Glucose Challenge

NCT03072602
View directory record Official record
Conditions
Healthy, Natriuretic Peptides, Metabolic Syndrome
Interventions
Study diet, Glucose Challenge
Dietary Supplement · Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 40 Years
Enrollment
81 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Oct 19, 2026, 4:56 PM EDT
Completed Phase 1 Interventional Results available

Roflumilast Plus Alogliptin Proof-of-Mechanism Study in Type2 Diabetes

NCT01664624
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Roflumilast, Alogliptin, Exenatide, Placebo to roflumilast, Placebo to alogliptin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
2
States / cities
Chula Vista, California • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Feb 1, 2017 · Synced Oct 19, 2026, 4:56 PM EDT
Completed No phase listed Observational

Lactate for Energy and Neurocognition

NCT05207397
View directory record Official record
Conditions
Healthy Aging, Alzheimer Disease
Interventions
Lactate infusion
Other
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
60 Years to 95 Years
Enrollment
24 participants
Timeline
2023 – 2024
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated May 14, 2025 · Synced Oct 19, 2026, 4:56 PM EDT
Recruiting Phase 2 Interventional

Screening Trial for Pain Relief in Schwannomatosis (STARFISH)

NCT05684692
View directory record Official record
Conditions
Schwannomatosis, Schwannomas, Pain, Chronic
Interventions
Siltuximab, Erenumab-Aooe, Siltuximab Matching Placebo, Erenumab-Aooe Matching Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 19, 2026, 4:56 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Study Investigating the Use of Intravenous Fluids With Dextrose for Dehydrated Children

NCT01343758
View directory record Official record
Conditions
Gastroenteritis, Dehydration
Interventions
5% dextrose in normal saline
Other
Lead sponsor
Boston Children's Hospital
Other
Eligibility
6 Months to 6 Years
Enrollment
188 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 24, 2012 · Synced Oct 19, 2026, 4:56 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Epigenetic Regulation of Human Adipose Tissue Distribution

NCT02728635
View directory record Official record
Conditions
Obesity
Interventions
Dual-energy X-ray absorptiometry (DEXA)/ Magnetic resonance imaging (MRI) and Magnetic resonance spectroscopy (MRS), Adipose tissue biopsies, FSIGTT/ RMR
Other · Procedure
Lead sponsor
AdventHealth Translational Research Institute
Other
Eligibility
18 Years to 45 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2026
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Oct 19, 2026, 4:56 PM EDT
Completed Phase 4 Interventional Results available

Eculizumab Pharmacokinetics/Pharmacodynamics Study in Pediatric/Adolescent Paroxysmal Nocturnal Hemoglobinuria (PNH)

NCT00867932
View directory record Official record
Conditions
Hemoglobinuria, Paroxysmal
Interventions
Eculizumab
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
2 Years to 17 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
3
States / cities
Orange, California • Pensacola, Florida • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 31, 2018 · Synced Oct 19, 2026, 4:56 PM EDT
Not listed Phase 1 Interventional

Use of Direct Peritoneal Resuscitation in High-risk Liver Transplant Recipients

NCT05195125
View directory record Official record
Conditions
End Stage Liver DIsease, Obesity, Acute Kidney Injury
Interventions
Direct Peritoneal Resuscitation
Procedure
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 8, 2023 · Synced Oct 19, 2026, 4:56 PM EDT
Completed Phase 1 Interventional

GIP: Glucose-dependent Insulinotropic Peptide

NCT00239707
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
GIP, Modified GIP, Normal Saline
Drug
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 28, 2013 · Synced Oct 19, 2026, 4:56 PM EDT
Completed Phase 2 Interventional Results available

Lurbinectedin in Patients With Advanced Gastrointestinal Malignancies With DNA Repair Mutations

NCT05229588
View directory record Official record
Conditions
Gastrointestinal Malignancies
Interventions
Lurbinectedin 4 MG Injection [Zepzelca]
Drug
Lead sponsor
HonorHealth Research Institute
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 19, 2026, 4:56 PM EDT
Terminated Phase 3 Interventional Results available

Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)

NCT03834493
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Pembrolizumab, Enzalutamide, Placebo
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older · Male only
Enrollment
1,244 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
28
States / cities
Mobile, Alabama • Fullerton, California • Los Angeles, California + 25 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 19, 2026, 4:56 PM EDT
Completed Phase 2 Interventional Results available

High-Dose Sequential Therapy and Single Autologous Transplantation for Multiple Myeloma

NCT00349778
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Cyclophosphamide, Etoposide, Melphalan, Carmustine, Filgrastim
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 75 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Dec 12, 2017 · Synced Oct 19, 2026, 4:56 PM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Reversing Glucose and Lipid-mediated Vascular Dysfunction

NCT04832009
View directory record Official record
Conditions
Blood Pressure, Hypertension
Interventions
Dextrose 20 % in 500 ML Injection, Intralipid, Saline, Ascorbic acid
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years to 79 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 5, 2025 · Synced Oct 19, 2026, 4:56 PM EDT